Oncology Medical News about non-Hodgkin lymphoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma
Leukemia and Lymphoma, 11/04/09

Katsuya H et al. – RTX seems to have a certain risk to induce IP including PCP. Patients with lymphoma who were treated by R–CHOP regimen, might be considered as PCP prophylactic, especially if the number of lymphocytes is low at the beginning of chemotherapy.

<< Previous
Disparities in medical care among commercially insured patients...

Next >>
Quantitative assessment of PTPN11 or RAS mutations at the...

Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09 Relevance Score: 68%

Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkins lymphoma: The Iowa Womens Health Study
International Journal of Cancer, 11/05/09 Relevance Score: 67%

Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma
Cancer Management and Research, 10/23/09 Relevance Score: 67%

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study : The Lancet Oncology
The Lancet Oncology - Online First, 10/12/09 Relevance Score: 67%

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
Journal of Clinical Oncology, 10/08/09 Relevance Score: 67%